Relmada Therapeutics Joins Russell 2000 and 3000 Indexes After June 26
RLMD•Relmada Therapeutics joined the Russell 2000 and Russell 3000 indexes following the June 26 reconstitution, increasing its exposure to small-cap and broad-market passive funds. The company cited robust 12-month NDV-01 NMIBC clinical data and a well-capitalized balance sheet as drivers for its elevated index inclusion.
1. Russell 2000 and 3000 Membership
Relmada Therapeutics joined the Russell 2000 and Russell 3000 indexes effective after market close on June 26, 2026, as part of the semi-annual Russell reconstitution. Inclusion exposes the company to index-linked passive funds measuring small-cap and broad-market performance, potentially boosting trading liquidity and institutional interest.
2. Clinical and Financial Drivers
The company highlighted robust 12-month clinical data for its lead candidate NDV-01 in non-muscle invasive bladder cancer and a well-capitalized balance sheet as key factors supporting its elevated market standing. These fundamental strengths underpin investor confidence ahead of upcoming mid-stage data readouts and funding milestones.
